Company Active LTD

Company profile

Roche Diagnostics Limited

Home

Today, Roche creates innovative medicines and diagnostic tests that help millions of patients globally

CRN
00571546
Founded
1956
Age
69

Overview

Legal name
ROCHE DIAGNOSTICS LIMITED
Region
South East England
Registered address
ROCHE HOUSE, CHARLES AVENUE
BURGESS HILL
WEST SUSSEX
RH15 9RY
Insolvency history
No

Corporate ownership

Updated 06 Jun 2026 16:52

2 levels 1 ultimate controller Controls 4
1
Company Active LTD
Roche Diagnostics Limited
CRN 00571546
2
Direct controller Active LTD
3
Ultimate controller
CH-270.3.005.159-0
CRN CH-270.3.005.159-0

Company events

Reference milestones and recent Companies House filing stream events.

8 events
30 Sep
2026

Accounts due

Accounts Due

Next accounts due date

13 Jun
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

04 Jun
2026

Confirmation Statement With No Updates

Confirmation-statement

CS01 | Transaction MzUyNTM2MTY0M2FkaXF6a2N4

Published 04 Jun 2026 10:52

07 Apr
2026

Termination Director Company With Name Termination Date

Officers

TM01 | Transaction MzUxNDc2OTAxOGFkaXF6a2N4

Published 07 Apr 2026 14:39

30 May
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Dec
2024

Accounts filed

Accounts

Last accounts made up date

11 Oct
2024

Accounts With Accounts Type Full

Accounts PDF pending

AA | Transaction MzQzODQ5OTIzM2FkaXF6a2N4 | Paper/PDF filed

Published 12 Oct 2024 06:51

14 Sep
1956

Incorporated

Inception

Company registered at Companies House

Public funding

5 awards
First funded
2019
Funded years
2019, 2020
Age at first award
62 years

Projects

2020 Collaborative R&D

iDx-LUNG - Integrating non-invasive diagnostics into NHSE Lung Health Checks in Wessex and Yorkshire

1 Nov 2020 to 30 Sep 2023

Awarded
£0
Total cost £815,400

The iDx-Lung programme brings together a consortium of academic institutions, NHS England Lung Health Checks and five commercial partners to accelerate progress in the early diagnosis of lung cancer. 15000 people from Wessex and Yorkshire attending for lung health checks at mobile CT scanners in the community will be asked to give samples of blood, and ce...

2020 Collaborative R&D

Integrated Diagnostics for Early Diagnosis of Liver Disease [ID-LIVER]

1 Sep 2020 to 31 Aug 2023

Awarded
£0
Total cost £1,208,199

Liver disease is an epidemic with up to four in ten people having health problems from their liver not working properly. A proportion of these patients develop scarring that is most commonly picked up late but which can progress without stopping to complete liver failure. It is one of the UK's largest health challenges for which we do not have answers. At...

2020 Collaborative R&D

The Integration and Analysis of Data using Artificial Intelligence to Improve Patient Outcomes with Thoracic Diseases (DART)

1 Jul 2020 to 31 Mar 2024

Awarded
£0
Total cost £5,909,676

We have assembled a team from academia, industry, charity and the NHS to integrate data from diagnostic technologies in novel ways using artificial intelligence algorithms. This will enable the earlier diagnosis of lung cancer for increased patient survival and large time and cost savings to the NHS. Lung cancer is the biggest cause of cancer death in the...

2020 Collaborative R&D

The ACTIONED Consortium: integrAted moleCular soluTIons fOr diagNostics and Early Detection

1 Feb 2020 to 30 Apr 2023

Awarded
£0
Total cost £4,117,761

ACTIONED (integrAted moleCular soluTIons fOr diagNostics and Early Detection) in a consortium of three main partners: 1.National leading experts in genomics/tissue-based cancer diagnostics (The Precision Medicine Centre of Excellence at Queen's University Belfast or PMC) 2.The leading global provider of diagnostic solutions in cancer genomics and tissue d...

2019 Collaborative R&D

NPIC: National Pathology Imaging Co-Operative

1 Feb 2019 to 31 Mar 2023

Awarded
£0
Total cost £1,540,000

"Pathologists are the **doctors who diagnose disease**. To do this, we examine samples (""biopsies"") using a microscope, to decide if a sample shows cancer, and what type of cancer it is. New scanners allow us to create digital images of microscope slides, so we can look at them on computers, and share them between hospitals more easily. This is called *...

Product types

Collaborative R&D